丹栀逍遥散联合Lucentis对新生血管性青光眼的临床疗效及血管通透因子和IL-6的影响  

Clinical Efficacy of Danzhi Xiaoyao Powder Combined with Lucentis on Neovascular Glaucoma and Effects on VPF and IL-6

作　　者：黄继琴 陈莉[2] 杨顺书 方一惟[1] Huang Jiqin;Chen Li;Yan Shunshu;Fang Yiwei(Department of Ophthalmology,Panzhihua City Central Hospital,Panzhihua 617067,China;Department of Traditional Chinese Medicine,Panzhihua City Central Hospital,Panzhihua 617067,China)

机构地区：[1]四川省攀枝花市中心医院眼科,攀枝花617067 [2]四川省攀枝花市中心医院中医科,攀枝花617067

出　　处：《世界中医药》2018年第8期1899-1902,1907,共5页World Chinese Medicine

基　　金：2014年度四川省卫生厅科研课题(140036)

摘　　要：目的:观察玻璃体腔内注射Lucentis联合丹栀逍遥散口服治疗新生血管性青光眼的临床疗效,并尝试对相关机制进行分析。方法:选取2015年1月至2017年6月攀枝花市中心医院收治的新生血管性青光眼患者56例(56眼),用随机数字表法将其分为对照组和观察组,每组28例(28眼),对照组予以玻璃体腔内注射Lucentis治疗,观察组在此基础上予丹栀逍遥散治疗,并观察治疗前后和随访6个月后患者眼压、视力、新生血管情况,并检测血清中血管通透因子(VPF)及IL-6水平,分析其疗效差异。结果:治疗后2组的眼压、视力、新生血管情况均较治疗前改善(P<0.05),且观察组优于对照组(P<0.05),且在随访6个月后,观察组的眼压、视力与新生血管情况仍优于对照组(P<0.05),同时在对2组患者的VPF、IL-6进行检测发现,观察组治疗后和随访6个月后的VPF、IL-6水平均明显低于对照组(P<0.05)。结论:丹栀逍遥散结合玻璃体腔内注射Lucentis是治疗新生血管性青光眼的有效治疗方法,再结合中药使用后,患者复发率更小,其作用机制可能与调控VPF、IL-6的水平有关。Objective： To observe the clinical effects of intravitreal injection of Lucentis combined with Danzhi Xiaoyao Powder oral treatment of neovascular glaucoma,and try to analyze the related mechanism. Methods： A total of 56 cases of neovascular glaucoma（ 56 eyes） in panzhihua city central hospital from January 2015 to June 2017 were randomly divided into control group and treatment group,with 28 cases in each group. The control group received intravitreal injection of Lucentis for treatment,and the treatment group was added Danzhi Xiaoyao Powder. The visual acuity,intraocular pressure of two groups of patients with neovascularization were observed before and after treatment and after 6 months of follow-up,and the serum VPF and IL-6 levels were observed.The differences of curative effect were analyzed. Results： After treatment,intraocular pressure,visual acuity,neovascularization of two groups were better than those before treatment（ P 〈0. 05）,and the treatment group was better than the control group（ P 〈0. 05）. After 6 months of follow-up,IOP and visual acuity and angiogenesis of the treatment group was better than that of the control group（ P 〈0. 05）. The VPF,IL-6 of two groups were detected after treatment and after 6 months of follow-up,and the VPF IL-6 was significantly lower than the control group,with statistical difference（ P 〈0. 05）. Conclusion： Danzhi Xiaoyao Powder combined with intravitreal injection of Lucentis is effective in the treatment of neovascular glaucoma. After combined use with traditional Chinese medicine,the recurrence rate is smaller,and it is worthy of clinical application. The effect of the mechanism may be related to the regulation of VPF and IL-6 levels.

关 键 词：丹栀逍遥散 新生血管性青光眼 血管通透因子 白细胞介素-6 作用机制 

分 类 号：R289.4[医药卫生—方剂学] R276.7[医药卫生—中药学]